Whooping cough,caused by Bordetella pertussis(Bp)infection,is an acute respiratory infectious disease in children transmitted through the air.Macrolide antibiotics have long been the first-line treatment for whooping cough.However,in recent years,macrolide-resistant Bordetella pertussis(MRBp)has been rarely reported outside China.The high prevalence of MRBp in China adds to the global challenge of whooping cough resurgence.The research firstly reports the emergence of clinical MRBp strains in China and has conducted extensive research in this field.This paper focuses on discussing the progress and challenges in the diagnosis,treatment and prevention of MRBp based on historical and recent studies.

The strikingly rapidly mutating nature of the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)genome has been a constant challenge during the coronavirus disease 2019(COVID-19)pandemic.In this study,various techniques,including reverse transcription-quantitative polymerase chain reaction,antigen-detection rapid diagnostic tests,and high-throughput sequencing were analyzed under different scenarios and spectra for the etiological diagnosis of COVID-19 at the population scale.This study aimed to summarize the latest research progress and provide up-to-date understanding of the methodology used for the evaluation of the immunoprotection conditions against future variants of SARS-CoV-2.Our novel work reviewed the current methods for the evaluation of the immunoprotection status of a specific population(endogenous antibodies)before and after vaccine inoculation(adminis-tered with biopharmaceutical antibody products).The present knowledge of the immunoprotection status regarding the COVID-19 complications was also discussed.Knowledge on the immunoprotection status of specific populations can help guide the design of pharmaceutical antibody products,inform practice guidelines,and develop national regulations with respect to the timing of and need for extra rounds of vaccine boosters.